Want to see DE:MRK full AI Analyst Report?
MRK Stock Chart & Stats
€139.15
€2.60(1.87%)
At close: 4:00 PM EDT
€139.15
€2.60(1.87%)
Day’s Range― - ―
52-Week Range€100.70 - €148.65
Previous CloseN/A
Volume239.25K
Average Volume (3M)321.00K
Market Cap
€62.24B
Enterprise Value€56.15K
Total Cash (Recent Filing)€3.77B
Total Debt (Recent Filing)€12.04B
Price to Earnings (P/E)24.6
Beta0.95
Next Earnings
Aug 06, 2026EPS Estimate
2.03Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)5.82
Shares Outstanding129,242,250
10 Day Avg. Volume344,164
30 Day Avg. Volume321,004
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)1.86
Price to Sales (P/S)2.53
P/FCF Ratio22.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€137.80Price Target Upside-0.97% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)8.03
Revenue Forecast (FY)€21.15B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelMerck KGaA's three-segment model spreads revenue across Healthcare, recurring Life Science consumables/services, and specialty Electronics materials. This diversification lowers single-market dependency, supports steadier revenue streams and cross-cycle resilience over a 2–6 month horizon.
Durable Profitability MarginsConsistently high gross and operating margins indicate pricing power and a value-added product mix. Durable margins support cash generation, fund R&D and capex, and provide buffer against revenue softness, sustaining the company's financial health over the medium term.
Manageable Leverage And Balance-sheet ResilienceModerate and improving leverage with rising equity suggests financial flexibility and capacity to absorb shocks. A stable balance sheet enables continued investment in core businesses and strategic moves without excessive refinancing risk in the coming months.
Bears Say
Weak Recent Revenue MomentumStalled and declining top-line trends constrain the firm's ability to grow operating profit and reinvest. If revenue weakness persists, it can force tougher allocation choices, pressure margins and capex plans, and slow recovery of growth over the next several quarters.
Cooling Returns On CapitalA meaningful drop in returns on equity signals decreasing efficiency in converting capital into profit. Lower ROE reduces shareholder return potential and may reflect structural pressures or larger capital bases, limiting near-term improvement without operational gains.
Only Moderate Cash ConversionFree cash flow has improved but remains a modest share of reported earnings and operating cash relative to revenue is low. Moderate cash conversion limits flexibility for large buybacks, aggressive M&A, or rapid de-leveraging if revenue headwinds persist.
MRK FAQ
What was Merck KGaA’s price range in the past 12 months?
Merck KGaA lowest stock price was €100.70 and its highest was €148.65 in the past 12 months.
What is Merck KGaA’s market cap?
Merck KGaA’s market cap is €62.24B.
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Merck KGaA’s earnings last quarter?
Merck KGaA released its earnings results on May 13, 2026. The company reported €2.11 earnings per share for the quarter, beating the consensus estimate of €1.947 by €0.163.
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Overvalued.
Does Merck KGaA pay dividends?
Merck KGaA pays a Annually dividend of €2.2 which represents an annual dividend yield of 1.54%. See more information on Merck KGaA dividends here
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is 2.03.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Merck KGaA reported an EPS of €2.11 in its last earnings report, beating expectations of €1.947. Following the earnings report the stock price went up 7.212%.
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in DE:MRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.96%
12-Months-Change
Fundamentals
Return on Equity
1.54%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Merck KGaA
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
MRK Stock 12 Month Forecast
Average Price Target
€137.80
▼(-0.97% Downside)
Technical Analysis
Evotec
―
Fresenius SE & Co. KGaA
―
Sartorius
―
Dermapharm Holding SE
―
Siemens Healthineers AG
―